Test of ovarian function suppression for low-risk premenopausal node+ breast cancer
Part of Cancer, Skin clinical trials.
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is ER-positive and HER2-negative (ER+ HER2-).
- You are premenopausal, and your age is 50 or younger.
- Your tumor is early stage (T1 or T2).
- Your lymph nodes are involved (N1), including tiny deposits called micrometastases.
- Your OncoFREE test result shows “genomic low risk” (a score from 1 to 20).
- You do not have ER-negative breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
This trial is testing a new treatment plan for women with high-risk breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It combines radiation therapy after surgery with a CDK4/6 inhibitor, which is a targeted therapy that helps stop cancer cells from dividing. The goal is to see if this combination is safe and well-tolerated, and it may help lower the chance of cancer coming back.
This study looks at young women with early-stage breast cancer who are premenopausal (still having periods) and have a low-to-intermediate Oncotype score, to see how well hormone therapy works. It aims to understand if current treatment decisions are appropriate.
This trial tests whether older women with very low-risk, hormone-positive breast cancer can safely skip endocrine therapy (hormone-blocking pills) and radiation after lumpectomy. It aims to maintain quality of life while keeping cancer from coming back.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.